PhD, MSc, BSc (Hons)
James Cook University
QLD | Australia
I began my professional life as a research scientist and progressed into public health to fulfil a desire to make a positive difference to the health of under-served populations based on two strategies. First, to teach research professionals the best way to undertake research whilst critically judging the evidence to improve their practice. Second to undertake research and help build research capability within the tropics, which is one of James Cook University’s strategic focus. While my high level statistical analysis skill allow me to be involved in, and support a diversity of research, my key strengths and passion is in applying public health principles in the detection, diagnosis, monitoring, therapy and management of chronic inflammatory diseases including peripheral artery disease and tuberculosis (TB).
Currently I am part of a team working on a project focussed on incorporating key elements of both innate and adaptive immune response and the pharmacodynamics and pharmacokinetics of current treatment regimen to explore the efficacy of various dosing combinations in optimising treatment regimen for multi-drug resistant TB.
Primary Affiliation: James Cook University - QLD , Australia
PubMed Central Citations
College of Medicine and Dentistry
James Cook University
School of Medicine and Dentistry
Mater Health Services and Mater Medical Research Institute
School of Medicine and Dentistry
University of Technology Sydney
University of Western Australia
James Cook University
University of Glasgow
78PubMed Central Citations
J Med Microbiol 2018 Aug 23. Epub 2018 Aug 23.
3Department of Infectious Diseases, Townsville Hospital, Douglas 4814, Australia.
J Paediatr Child Health 2018 Jun 4. Epub 2018 Jun 4.
Public Health and Tropical Medicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia.
Aust N Z J Obstet Gynaecol 2018 May 22. Epub 2018 May 22.
College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia.
Mycoses 2018 Apr 17. Epub 2018 Apr 17.
Infection Management Services, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Arch Environ Occup Health 2018 Apr 27:1-14. Epub 2018 Apr 27.
a Public Health and Tropical Medicine , College of Public Health, Medical and Veterinary Sciences, James Cook University , Townsville QLD , Australia.
Emerg Med Australas 2017 Aug 18;29(4):383-390. Epub 2017 Jun 18.
Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Clin Sci (Lond) 2017 Jun 7;131(12):1261-1281. Epub 2017 Jun 7.
The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland 4811, Australia
J Clin Nurs 2017 Apr 23;26(7-8):1021-1030. Epub 2016 Nov 23.
Faculty of Science, Charles Sturt University, Bathurst, New South Wales, Australia.
Front Cardiovasc Med 2017 23;4:16. Epub 2017 Mar 23.
Queensland Research Centre for Peripheral Vascular Diseases, College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia; Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, QLD, Australia.
Vol5 Issue1, EJCM .January 2017
European Journal of Cardiovascular Medicine
Objective: This study was done to assess the safety and efficacy of aspirin in the initial treatment and secondary prevention of acute stroke of undetermined or presumed ischemic etiology. Background: The use of aspirin for the initial treatment of acute stroke of unknown etiology in low-resource settings is often challenged by the lack of diagnostic brain imaging to confirm specific stroke type and guide treatment. Aspirin use carries a potential risk of causing or exacerbating cerebral hemorrhage which can be fatal or disabling. Hence, in developing countries only 3.8% of acute stroke patients take antiplatelet compared to 53.1% in high income countries. Methods: A systematic review of literature from the Cochrane library, Medline, Scopus and Google Scholar was done. Studies 1) involving patients with acute stroke of undetermined or presumed ischemic etiology, 2) involving the use of aspirin in the initial treatment and/or secondary prevention of acute stroke of unknown or presumed ischemic etiology, and 3) comparing aspirin to a control or other antiplatelet agent (s), were selected for the review. Results: There was homogeneity of results in support of aspirin use for the initial treatment and secondary prevention of acute stroke of unknown etiology. The studies showed significant reduction in in-hospital mortality, disability, stroke recurrence and risk of hemorrhagic stroke with the use of aspirin. Conclusion: Available evidence supported the use of aspirin for the initial treatment and secondary prevention of acute stroke of unknown or presumed ischemic etiology in resource-constrained settings, where brain imaging is unavailable to confirm stroke type.
Biomedicines 2016, 4, 20.
Pancreatic cancer is an aggressive disease with a five year survival rate of less than 5%, which is associated with late presentation. In recent years, research into nanomedicine and the use of nanoparticles as therapeutic agents for cancers has increased. This article describes the latest developments in the use of nanoparticles, and evaluates the risks and benefits of nanoparticles as an emerging therapy for pancreatic cancer. The Preferred Reporting Items of Systematic Reviews and Meta-Analyses checklist was used. Studies were extracted by searching the Embase, MEDLINE, SCOPUS, Web of Science, and Cochrane Library databases from inception to 18 March 2016 with no language restrictions. Clinical trials involving the use of nanoparticles as a therapeutic or prognostic option in patients with pancreatic cancer were considered. Selected studies were evaluated using the Jadad score for randomised control trials and the Therapy CA Worksheet for intervention studies. Of the 210 articles found, 10 clinical trials including one randomised control trial and nine phase I/II clinical trials met the inclusion criteria and were analysed. These studies demonstrated that nanoparticles can be used in conjunction with chemotherapeutic agents increasing their efficacy whilst reducing their toxicity. Increased efficacy of treatment with nanoparticles may improve the clinical outcomes and quality of life in patients with pancreatic cancer, although the long-term side effects are yet to be defined. The study registration number is CRD42015020009.
Clin Sci (Lond) 2016 Mar;130(5):301-15
Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, James Cook Drive, Douglas, Townsville, QLD 4811, Australia Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, QLD 4814, Australia
Int J Clin Case Stud 2015, 1: 109
International Journal of Clinical Case Studies
Eclampsia is characterised by the occurrence of one or more generalised tonic-clonic seizures in patients with severe preeclampsia in the absence of other neurologic conditions. The clinical features of eclampsia can present at any time during pregnancy, but are more common from the second trimester to the puerperium. This report presents the challenges encountered in the management of eclampsia in a remote setting of a developing country and the influence of cultural and socio-economic factors on health outcomes associated with this condition.
Annals of the Australasian College of Tropical Medicine, 17 (1). p. 19
Annals of the Australasian College of Tropical Medicine
Background/Aims: Pancreatic cancer is the fourth most common cause of cancer associated death worldwide with a five year survival rate less than 5%. The poor prognosis is mainly due to late presentation in 80% of patients and its drug resistant nature. Most diagnoses are made using contrast-enhanced computed-tomography (CT) or magnetic-resonance-imaging (MRI) which have a limited sensitivity between 76-86%. Iron oxide nanoparticles are increasingly used in the diagnostic imaging of pancreatic cancer, due their ability to selectively target tumour cells thereby increasing image resolution. The aim of this study is to identify studies investigating the use of iron oxide nanoparticles in the diagnostic imaging of pancreatic cancer. Methods: A systematic review was performed using PubMed for records up to 2015. Search terms used included “iron oxide nanoparticles”, “pancreatic cancer” and “imaging”. Results: A total of 16 studies were identified evaluating the use of iron oxide nanoparticles in the imaging of pancreatic cancer in-vitro and in in-vivo animal models. Eight of the studies evaluated the use of superparamagnetic-iron-oxide-nanoparticles (SPION), they showed SPION significantly decrease the T2 and T2* relaxation times of tumour tissue, providing a high sensitivity for MRI. Similar results were seen in eight studies that investigated the use of iron oxide nanoparticles conjugated to other molecules including gelatin, survivin, chemokine-receptor-4, silica-gold, endothelial-growth-factor-receptor, urokinase-receptor activator, Clostridium and a sonic-hedgehog target. Conclusion: Iron oxide nanoparticles in the form of SPION or conjugates are biocompatible and effective at targeting tumour cells and significantly attenuate MRI signals in T2-weighted images of pancreatic cancers from a range of cell lines.
Brain Pathol 2015 May 30;25(3):237-47. Epub 2014 Oct 30.
The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.
Proteomics Clin Appl 2014 Oct 19;8(9-10):762-72. Epub 2014 May 19.
Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, Townsville, Australia.
Clin Sci (Lond) 2014 Apr;126(7):517-27
*The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, James Cook Drive, Douglas, Townsville, QLD 4811, Australia.
Anadolu Kardiyol Derg 2012 Mar 26;12(2):121-2. Epub 2012 Jan 26.